Amicus Therapeutics Company Insiders

FOLD Stock  USD 11.78  0.08  0.67%   
Amicus Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Amicus Therapeutics suggests that all insiders are panicking. Amicus Therapeutics employs about 517 people. The company is managed by 41 executives with a total tenure of roughly 317 years, averaging almost 7.0 years of service per executive, having 12.61 employees per reported executive.
John Crowley  Chairman
Executive Chairman
Hung Do  President
Senior Vice President - Discovery Biology

Amicus Therapeutics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-03-05Margaret G McglynnDisposed 7500 @ 13.4View
2024-02-15Bradley L CampbellDisposed 4167 @ 14View
2024-02-06Ellen RosenbergDisposed 400 @ 13View
2024-01-22John F CrowleyDisposed 55327 @ 12.36View
2024-01-16John F CrowleyDisposed 31614 @ 12.78View
2024-01-10John F CrowleyDisposed 31614 @ 13.65View
2024-01-09David Michael ClarkDisposed 1384 @ 14View
2024-01-08Samantha ProutDisposed 30767 @ 14View
2024-01-02Bradley L CampbellDisposed 15833 @ 14.23View
2023-12-27Ellen RosenbergDisposed 5000 @ 14.07View
2023-12-26Samantha ProutDisposed 7659 @ 14View
2023-12-19Jeff CastelliDisposed 17500 @ 13.25View
2023-12-15John F CrowleyDisposed 6043 @ 12.66View
2023-12-01John F CrowleyDisposed 6043 @ 11.08View
2023-11-15John F CrowleyDisposed 6043 @ 10.84View
2023-11-01John F CrowleyDisposed 6044 @ 10.97View
Monitoring Amicus Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Amicus Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Amicus Therapeutics' future performance. Based on our forecasts, it is anticipated that Amicus will maintain a workforce of about 520 employees by April 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Amicus Therapeutics' latest congressional trading

Congressional trading in companies like Amicus Therapeutics, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Amicus Therapeutics by those in governmental positions are based on the same information available to the general public.
2023-04-10Representative Daniel GoldmanDisposed Under $15KVerify

Amicus Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.0612) % which means that it has lost $0.0612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0704) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 29, 2024, Return On Capital Employed is expected to decline to -0.13. In addition to that, Return On Assets is expected to decline to -0.2. At present, Amicus Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 7.23, whereas Other Assets are forecasted to decline to about 41.8 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 309.9 M, whereas Net Loss is forecasted to decline to (223.6 M).

Amicus Therapeutics Workforce Comparison

Amicus Therapeutics is rated # 2 in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 1,497. Amicus Therapeutics totals roughly 517 in number of employees claiming about 35% of equities under Health Care industry.

Amicus Therapeutics Profit Margins

The company has Profit Margin (PM) of (0.38) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.03) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.03.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.70.8868
Significantly Down
Very volatile

Amicus Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amicus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amicus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Amicus Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
0.4386
25
57
 1,628,934 
 995,200 
2023-12-01
0.4348
10
23
 148,755 
 244,055 
2023-09-01
0.3
9
30
 368,025 
 380,794 
2023-06-01
1.4
21
15
 362,564 
 129,764 
2023-03-01
0.5
25
50
 2,630,315 
 1,056,570 
2022-12-01
0.2
3
15
 16,425 
 212,069 
2022-09-01
0.1579
3
19
 16,410 
 147,312 
2022-06-01
1.0
15
15
 490,901 
 189,862 
2022-03-01
0.7692
20
26
 2,364,302 
 422,148 
2021-12-01
0.3913
9
23
 112,219 
 340,543 
2021-09-01
0.6316
12
19
 112,206 
 257,842 
2021-06-01
1.3636
45
33
 892,615 
 1,539,199 
2021-03-01
0.7436
29
39
 1,094,452 
 540,130 
2020-12-01
0.5814
25
43
 436,879 
 966,785 
2020-09-01
0.6545
36
55
 633,805 
 1,263,958 
2020-06-01
0.9268
38
41
 455,820 
 457,348 
2020-03-01
0.597
40
67
 2,556,403 
 1,026,752 
2019-12-01
0.3889
7
18
 780,082 
 347,946 
2019-09-01
0.6667
4
6
 64,945 
 120,000 
2019-06-01
1.7059
29
17
 540,944 
 235,205 
2019-03-01
1.0313
33
32
 2,034,966 
 652,206 
2018-12-01
1.3333
4
3
 180,854 
 20,000 
2018-09-01
1.2857
9
7
 719,205 
 45,000 
2018-06-01
1.2353
21
17
 132,863 
 238,277 
2018-03-01
1.0625
34
32
 1,424,615 
 322,879 
2017-12-01
0.4074
22
54
 1,303,224 
 2,643,661 
2017-09-01
1.6667
5
3
 1,507,185 
 4,185 
2017-06-01
2.5
20
8
 234,264 
 102,250 
2017-03-01
4.0
20
5
 1,905,643 
 250,000 
2016-12-01
1.75
7
4
 514,508 
 55,716 
2016-09-01
0.125
1
8
 3,500 
 1,205,374 
2016-03-01
1.75
14
8
 1,175,000 
 205,874 
2015-12-01
2.4286
17
7
 919,443 
 90,006 
2015-09-01
0.4375
14
32
 267,511 
 511,316 
2015-06-01
0.6341
52
82
 1,955,240 
 1,150,894 
2015-03-01
0.6591
29
44
 1,362,904 
 913,280 
2014-12-01
0.5
19
38
 2,343,737 
 11,822,181 
2014-09-01
0.5152
17
33
 305,347 
 317,694 
2014-06-01
41.0
41
1
 5,851,491 
 16,491 
2014-03-01
2.0
16
8
 1,091,608 
 445,175 
2013-12-01
0.4
2
5
 20,000 
 65,000 
2013-03-01
1.1111
10
9
 593,756 
 132,000 
2012-09-01
1.0
1
1
 30,000 
 10,000 
2012-06-01
7.0
14
2
 778,750 
 205,000 
2012-03-01
14.0
14
1
 3,730,085 
 49,931 
2011-06-01
4.3333
13
3
 457,250 
 14,500 
2011-03-01
0.4706
8
17
 360,000 
 190,000 
2010-06-01
2.0
10
5
 217,500 
 67,834 
2010-03-01
2.0
2
1
 23,796 
 9,500 
2009-12-01
1.2
6
5
 420,000 
 44,835 
2009-06-01
1.0
3
3
 30,000 
 12,791 
2009-03-01
0.8889
8
9
 293,924 
 17,834 
2008-12-01
0.0303
3
99
 60,098 
 202,390 
2008-06-01
0.0327
7
214
 90,000 
 71,250 
2008-03-01
34.9565
1608
46
 1,658,581 
 122,583 
2007-12-01
1.0
2
2
 15,000 
 15,000 
2007-09-01
105.0
105
1
 261,460 
 32,366 
2007-06-01
2.1628
186
86
 33,414,058 
 15,594,354 

Amicus Therapeutics Notable Stakeholders

An Amicus Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Amicus Therapeutics often face trade-offs trying to please all of them. Amicus Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Amicus Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Bradley MBAPresident CEOProfile
John CrowleyExecutive ChairmanProfile
Hung DoSenior Vice President - Discovery BiologyProfile
John KirkVice President - Regulatory AffairsProfile
Andrew MulbergVice President - Regulatory StrategyProfile
Enrique DiloneVice President - Technical OperationsProfile
Dipal DoshiSenior Vice President - Business Planning and DevelopmentProfile
Mark BaldryVice President of Global MarketingProfile
Kenneth PeistVice President - Legal and Intellectual PropertyProfile
Ken ValenzanoSenior Vice President - Preclinical ResearchProfile
Jayne GershkowitzVice President - Patient Advocacy & Public PolicyProfile
Willem WeperenRegional Vice President and Country Manager, InternationalProfile
Julie YuVice President - Clinical Operations and Data ManagementProfile
David AllsopSenior Vice President - InternationalProfile
Simon JordanSenior Vice President - InternationalProfile
Jill WeimerSenior Vice President of Discovery Research and Gene Therapy ScienceProfile
Jeffrey CastelliVice President - Program and Portfolio ManagementProfile
Kurt AndrewsSenior Vice President - Human ResourcesProfile
William BairdCFOProfile
Bradley CampbellPres and COOProfile
Robert EssnerIndependent DirectorProfile
Craig WheelerIndependent DirectorProfile
Burke WhitmanIndependent DirectorProfile
Margaret McGlynnIndependent DirectorProfile
Ted LoveIndependent DirectorProfile
Donald HaydenLead Independent DirectorProfile
Michael RaabIndependent DirectorProfile
Sol BarerIndependent DirectorProfile
Lynn BleilIndependent DirectorProfile
Glenn SblendorioIndependent DirectorProfile
Daphne QuimiPrincipal Accounting Officer, VP of Fin. and Corporate ControllerProfile
David ClarkChief OfficerProfile
Samantha ProutPrincipal Accounting Officer, ControllerProfile
Andrew FaughnanDirector RelationsProfile
Diana MooreHead CommunicationsProfile
Jay BarthChief Medical OfficerProfile
Patrik EsqGlobal OfficerProfile
Sara PellegrinoIR Contact OfficerProfile
Patrik FlorencioGlobal VPProfile
Simon HarfordChief OfficerProfile
Ellen RosenbergGeneral Counsel and Corporate SecretaryProfile

About Amicus Therapeutics Management Performance

The success or failure of an entity such as Amicus Therapeutics often depends on how effective the management is. Amicus Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Amicus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Amicus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2024
Return On Capital Employed(0.12)(0.13)
Return On Assets(0.19)(0.20)
Return On Equity(0.95)(0.99)
The data published in Amicus Therapeutics' official financial statements usually reflect Amicus Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Amicus Therapeutics. For example, before you start analyzing numbers published by Amicus accountants, it's critical to develop an understanding of what Amicus Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Amicus Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amicus Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Amicus Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amicus Therapeutics. Please utilize our Beneish M Score to check the likelihood of Amicus Therapeutics' management manipulating its earnings.

Amicus Therapeutics Workforce Analysis

Traditionally, organizations such as Amicus Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Amicus Therapeutics within its industry.

Amicus Therapeutics Manpower Efficiency

Return on Amicus Therapeutics Manpower

Revenue Per Employee772.4K
Revenue Per Executive9.7M
Net Loss Per Employee293.2K
Net Loss Per Executive3.7M
Working Capital Per Employee610K
Working Capital Per Executive7.7M
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.51)
Revenue Per Share
1.353
Quarterly Revenue Growth
0.306
Return On Assets
(0.06)
Return On Equity
(1.07)
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.